miR-29b binding site on human progranulin (GRN) mRNA 3' UTR (GRN 3' UTR miR-29b site)

The miR-29b binding site on the human progranulin (GRN) mRNA 3' untranslated region (UTR) is a specific sequence that serves as a regulatory hub for the post-transcriptional modulation of progranulin expression. MicroRNA-29b (miR-29b) recognizes and binds to this site, leading to the downregulation of progranulin protein synthesis through translational inhibition or mRNA decay (Jiao et al., 2010, PubMed: 20107045). Progranulin is a multifunctional protein essential for lysosomal function and neuronal survival, and its deficiency is a major genetic cause of frontotemporal dementia (FTD) (Rademakers et al., 2012, PubMed: 22901937). This binding site has emerged as a therapeutic target for antisense oligonucleotides (ASOs) known as target site blockers (TSBs). These ASOs are designed to sterically hinder the interaction between miR-29b and the GRN mRNA, thereby boosting the production of progranulin from the remaining healthy allele in patients with GRN mutations. Clinical development of such therapies, like VAV-101, focuses on restoring progranulin levels to neuroprotective ranges while monitoring for potential off-target effects or risks associated with progranulin overexpression (Vavaris, 2021). By specifically blocking the miRNA-mRNA interaction without degrading the mRNA itself, this approach offers a precise method to upregulate a target protein. Success in this area could provide a blueprint for treating other haploinsufficiency-related neurodegenerative diseases.

Other names

Progranulin 3' UTR miR-29b binding siteGRN 3' UTR miR-29b target sitePGRN 3' UTR miR-29b binding sitehGRN 3' UTR miR-29b-binding elementMicroRNA-29b response element in GRN 3' UTR

Steric hindrance of microRNA binding (Target Site Blocker)